ABBV · 10-Q · 2026Q2 · Full report
Product Pipeline Progress
AbbVie Inc. · 2026-08-03 · Importance 5 · Surprise 30 · In source text
AbbVie’s development pipeline includes approximately 90 compounds, devices or indications, including approximately 60 programs in mid- and late-stage development. The pipeline is focused on immunology, neuroscience, oncology, aesthetics and obesity, with multiple mid-stage programs expected to advance to late-stage development over the next 12 months. The company initiated Phase 3 studies for ABBV-706 in relapsed/refractory small cell lung cancer and Temab-A in refractory metastatic colorectal cancer. Epkinly’s EPCORE DLBCL-4 trial met its primary endpoint by improving progression-free survival, while the EPCORE DLBCL-1 trial did not demonstrate a statistically significant overall-survival improvement.
Key facts
- AbbVie expects multiple mid-stage programs to transition into late-stage programs in the next 12 months. source
- In June 2026 AbbVie announced topline Phase 3 EPCORE DLBCL-4 results showing Epkinly plus lenalidomide met its primary endpoint demonstrating improvement in progression free survival. source
- In April 2026 AbbVie initiated a Phase 3 trial to evaluate ABBV-706 versus standard of care in R/R small cell lung cancer. source
- In June 2026 AbbVie initiated a Phase 3 trial to evaluate Temab-A plus bevacizumab versus LONSURF plus bevacizumab in refractory metastatic colorectal cancer. source
- In February 2026 AbbVie announced positive topline Phase 3 AFFIRM trial results for Skyrizi subcutaneous induction in adult patients with moderately to severely active Crohn’s disease. source
- In January 2026 AbbVie announced topline Phase 3 EPCORE DLBCL-1 results for Epkinly in R/R DLBCL showing the study did not demonstrate a statistically significant improvement in overall survival. source
- AbbVie’s pipeline includes approximately 90 compounds, devices or indications in development, of which approximately 60 are in mid- and late-stage development. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | AbbVie expects multiple mid-stage programs to transition into late-stage programs in the next 12 months. |
| revenue | positive | probable | — | In June 2026 AbbVie announced topline Phase 3 EPCORE DLBCL-4 results showing Epkinly plus lenalidomide met its primary endpoint… |
| operating_income | negative | committed | — | In April 2026 AbbVie initiated a Phase 3 trial to evaluate ABBV-706 versus standard of care in R/R small cell lung cancer. |
| operating_income | negative | committed | — | In June 2026 AbbVie initiated a Phase 3 trial to evaluate Temab-A plus bevacizumab versus LONSURF plus bevacizumab in refractory… |